{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T02:51:16Z","timestamp":1789872676466,"version":"4.0.1"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,1,2]]},"DOI":"10.1097\/qad.0b013e32833032ed","type":"journal-article","created":{"date-parts":[[2009,11,28]],"date-time":"2009-11-28T08:17:41Z","timestamp":1259396261000},"page":"55-65","source":"Crossref","is-referenced-by-count":98,"title":["Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial"],"prefix":"10.1097","volume":"24","author":[{"given":"Anton L","family":"Pozniak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Morales-Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elly","family":"Katabira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewald","family":"Steyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio H","family":"Lupo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Santoscoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Grinsztejn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiat","family":"Ruxrungtham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence T","family":"Rimsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Vanveggel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Boven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210130","doi-asserted-by":"crossref","first-page":"6221","DOI":"10.1074\/jbc.C300523200","article-title":"Defining a molecular mechanism of synergy between nucleoside and nonnucleoside AIDS drugs","volume":"279","author":"Basavapathruni","year":"2004","journal-title":"J Biol Chem"},{"key":"R2-8-20210130","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1310\/LNHD-K1R7-HQP5-HJCQ","article-title":"Higher rates of viral suppression with nonnucleoside reverse transcriptase inhibitors compared to single protease inhibitors are not explained by better adherence","volume":"5","author":"Weiser","year":"2004","journal-title":"HIV Clin Trials"},{"key":"R3-8-20210130","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1097\/00002030-200112070-00008","article-title":"Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an antiatherogenic lipid profile","volume":"15","author":"van der Valk","year":"2001","journal-title":"AIDS"},{"key":"R4-8-20210130","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00003495-200161010-00003","article-title":"The emerging roles of nonnucleoside reverse transcriptase inhibitors in antiretroviral therapy","volume":"61","author":"Moyle","year":"2001","journal-title":"Drugs"},{"key":"R5-8-20210130","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa074609","article-title":"Class-sparing regimens for initial treatment of HIV-1 infection","volume":"358","author":"Riddler","year":"2008","journal-title":"N Engl J Med"},{"key":"R6-8-20210130","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1097\/01.aids.0000131310.52526.c7","article-title":"The prevalence of antiretroviral drug resistance in the United States","volume":"18","author":"Richman","year":"2004","journal-title":"AIDS"},{"key":"R7-8-20210130","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S0026-895X(25)08931-X","article-title":"In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to nonnucleoside inhibitors of reverse transcriptase","volume":"41","author":"Mellors","year":"1992","journal-title":"Mol Pharmacol"},{"key":"R8-8-20210130","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1128\/JVI.68.3.1660-1666.1994","article-title":"Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy","volume":"68","author":"Richman","year":"1994","journal-title":"J Virol"},{"key":"R9-8-20210130","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1089\/aid.1994.10.39","article-title":"Characterization of HIV-1 strains isolated from patients treated with TIBO R82913","volume":"10","author":"Vandamme","year":"1994","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R10-8-20210130","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/jmv.2055","article-title":"Resistance profile and cross-resistance of HIV-1 among patients failing a nonnucleoside reverse transcriptase inhibitor-containing regimen","volume":"65","author":"Delaugerre","year":"2001","journal-title":"J Med Virol"},{"key":"R11-8-20210130","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1089\/08892220260190308","article-title":"Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure","volume":"18","author":"Antinori","year":"2002","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R12-8-20210130","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1310\/3Q91-YT2D-BUT4-8HN6","article-title":"Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients","volume":"3","author":"Perez-Molina","year":"2002","journal-title":"HIV Clin Trials"},{"key":"R13-8-20210130","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(04)15997-7","article-title":"Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study","volume":"363","author":"van Leth","year":"2004","journal-title":"Lancet"},{"key":"R20-8-20210130","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1021\/jm040840e","article-title":"In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine)","volume":"48","author":"Janssen","year":"2005","journal-title":"J Med Chem"},{"key":"R21-8-20210130","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1073\/pnas.0711209105","article-title":"High-resolution structures of HIV-1 reverse transcriptase\/TMC278 complexes: strategic flexibility explains potency against resistance mutations","volume":"105","author":"Das","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R22-8-20210130","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1097\/01.aids.0000242818.65215.bd","article-title":"Short-term antiviral activity of TMC278 - a novel NNRTI \u2013 in treatment-na\u00efve HIV-1-infected subjects","volume":"20","author":"Goebel","year":"2006","journal-title":"AIDS"},{"key":"R24-8-20210130","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2307\/2529712","article-title":"Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial","volume":"31","author":"Pocock","year":"1975","journal-title":"Biometrics"},{"key":"R27-8-20210130","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"R28-8-20210130","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/01.qai.0000245886.51262.67","article-title":"Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine\/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes \u2013 a 96-week analysis","volume":"43","author":"Pozniak","year":"2006","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/QAD.0b013e32833032ed","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T13:36:37Z","timestamp":1739453797000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002030-201001020-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,2]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e32833032ed","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1,2]]}}}